Company

Company

Overview

NaNotics is a Delaware LLC with headquarters in Mill Valley, CA, just north of San Francisco. NaNotics is developing an advanced nanomedical platform for treating major human and animal diseases. Our management team and Scientific Advisory Board members are profiled below, and our funding history is here. The company leverages multiple vendor and joint development relationships, especially for nano fabrication and design of capture agents. We are open to additional vendors and partnerships so please reach out if you feel you have something to offer.

Management

Founder - CEO

Lou Hawthorne

Co-founder - CTO

John Dodgson, PhD

CFO

Song Schreiber, MS, MBA

CDO

Graeme Currie, PhD

VP of Veterinary R & D

Michael Levenson, VMD

CMO

Keith Block, MD

Founder - CEO

Lou Hawthorne

Lou Hawthorne is the founder and CEO of NaNotics, LLC, and is the inventor of the company’s core technology. Lou is an entrepreneur with 25 years’ experience in founding and leading companies developing new technologies in biotech/life science and information technology, including reproductive cloning, human IVF, oncology, and artificial intelligence.

In 2002, Lou co-founded the cloning companies Genetic Savings & Clone, and Viagen, Inc. acquired by Intrexon (XON) in 2014.

In 2014, Lou conceived and developed the concept of immune modulating nano-extractors (‘NaNots’), and founded NaNotics LLC., which is currently developing NaNots for treating cancer, sepsis, autoimmune disease and aging.

Lou is an experienced company leader with an extensive track record in funding, assembling and managing senior level multi-disciplinary teams for effective development of new technologies. He has collaborated closely with company co-founder, John Dodgson, PhD, a physical chemist and IP expert, for nearly two decades.

Lou is also an expert at brand development and strategic media, having designed global media campaigns that reached millions of people and generated profile valued at hundreds of millions of dollars. He has been interviewed by most major newspapers, magazines, and television programs, including appearances on The Oprah Winfrey Show and Good Morning America.

Lou holds a B.A. in English Literature from Princeton University, where he was a University Scholar and recipient of the Ward Mathis prize.

Co-founder - CTO

John Dodgson, PhD

  • NaNotics co-founder
  • PhD, Newcastle University (physical chemistry)
  • Expert in micro & nano bio-engineering
  • IP creation (30+ patents), analysis & drafting
  • Very familiar with cancer immunotherapy & pheresis
  • Pioneer in microfluidics, especially as applied to cloning & IVF

CFO

Song Schreiber, MS, MBA

  • University of California Santa Cruz
  • Managed law office of Mayor of San Francisco
  • Managed multimillion-dollar revenue & investments
  • Extensive political & legal strategic experience
  • Extensive experience with pharma & healthcare companies & CEOs

CDO

Graeme Currie, PhD

Dr. Currie has been consulting for NaNotics for the past two years and recently committed to join as CDO upon close of the Company’s Series B, increasing his consulting in the interim. Dr. Currie has over 25 years of drug development experience in both pharmaceutical and biotechnology companies. Dr. Currie was most recently VP of Clinical Science and Operations at Dynavax Technologies Corp. Prior to that, he spent six years at Regeneron Pharmaceuticals as the VP of Clinical Project Management & Operations, and oversaw operations for 16 molecules and multiple therapeutic areas. During his tenure, Dr. Currie was closely associated with the development programs for Eylea® for Wet AMD and DME, Praluent® for hypercholesterolemia and Dupixent® for Atopic Dermatitis. Prior to Regeneron, Dr. Currie was VP of Clinical Operations at Sepracor Inc. and at PDL Biopharma. Graeme also spent 6 years as a Director at Gilead Sciences Inc., working in Hepatitis developing Hepsera™ for Chronic Hepatitis B. Prior to Gilead, he had roles at IPSEN Biopharmaceuticals Inc. and Glaxo Wellcome. Graeme received a BSc from the University of Salford, and a Ph.D. in Oncology from Aston University.

VP of Veterinary R & D

Michael Levenson, VMD

  • VMD, University of Pennsylvania, Philadelphia, PA
  • Immunotherapy research and canine clinical trials experience
  • Brings a translational medicine “one health” approach to nanoparticle immunotherapy R&D
  • Practicing emergency veterinarian (Marin County, CA) with clinical focus in critical care medicine, surgery, and oncology

CMO

Keith Block, MD

  • MD, University of Miami
  • 35 years integrative oncology
  • Medical Dir, Block Center for Integrative Cancer Treatment
  • Adjunct Professor, University of Illinois at Chicago
  • Editor-in-Chief, Integrative Cancer Therapies (SagePub)
  • Editorial Board, Physicians Data Query Cancer CAM, National Cancer Institute

Advisory Board

Heiko Rieger, PhD

Stephan Lensky, PhD

Kevin Perrott, PhD

Margaretta Colangelo

Mitch Harman,
 MD, PhD

Mike Eaton, PhD

Wayne Jonas, MD

Shazib Pervaiz, MBBS, PhD

Brian Kennedy, PhD

Aubrey de Grey, PhD

Jonathan Milner, PhD

Robert Skalik, MD, PhD

Heiko Rieger, PhD

  • Professor of Theoretical Physics, Saarland University, Germany
  • Expert: Tumor Modeling

Stephan Lensky, PhD

  • Chief Operating and Chief Business Officer of EpimAb

Kevin Perrott, PhD

  • Scientist, Buck Institute SENS Research Foundation
  • Exec. Director, Methuselah Prize
  • President, Global Healthspan Policy Institute

Margaretta Colangelo

  • Co-founder and Managing Director of Deep Knowledge Group
  • Co-founder and Managing Partner of Longevity Capital
  • Co-founder Deep Knowledge Analytics
  • Co-founder Aging Analytics Agency
  • Co-founder Longevity Bank
  • Co-founder Jthereum
  • President U1 Technologies
  • Over 30 years of experience in executive management in software companies in Silicon Valley
  • Author of over 100 articles on AI, DeepTech, and The Longevity Industry
  • Co-author of Longevity Industry 1.0: Defining the Biggest and Most Complex Industry in Human History

Mitch Harman,
 MD, PhD

  • Chief, Endocrinology Section, Department of Medicine at VA, National Institute on Aging
  • Former Chief, Laboratory of Clinical Investigation (LCI)

Mike Eaton, PhD

  • Professor, Nottingham University
  • Charter Executive Board Member, European Technology Platform for Nanomedicine

Wayne Jonas, MD

  • Integrative Health Expert, Family Physician, Researcher, and Author
  • Former Director NIH Office of Alternative Medicine
  • Former Director World Health Organization Center for Traditional Medicine
  • Former Director of Medical Research Fellowship at Walter Reed Army Institute of Research
  • Retired Lt. Colonel United States Army Medical Corps
  • Practicing Family Physician at Fort Belvoir Community Hospital Pain Clinic
  • Clinical Professor of Family Medicine, Georgetown University
  • Executive Director of Samueli Integrative Health Programs

Shazib Pervaiz, MBBS, PhD

  • Professor, Yong Loo Lin School of Medicine, NUS
  • Expert: Cancer Cell Signals
  • Fellowships: Harvard Medical, Mass General

Brian Kennedy, PhD

  • CEO, Buck Institute for Research on Aging
  • Professor in Medicine & Healthy Aging, National University Singapore

Aubrey de Grey, PhD

  • CSO, SENS Research Foundation International
  • Expert: Aging

Jonathan Milner, PhD

  • Founder, Abcam, PLC
  • Investor in 40 companies
    (3 successful IPOs)

Robert Skalik, MD, PhD

  • Consultant cardiologist (general cardiology, cardiac imaging techniques, sports cardiology), senior lecturer in human physiology
  • Wroclaw Medical University, Poland
  • Elected Overseas Fellow of Royal Society of Medicine (London, UK)
  • Practicing consultant cardiologist at Specialist Hospital With Outpatient Clinics „Ventriculus”, Leszno and PZU Health Centre in the city of Wroclaw, Poland
  • Former adjunct professor of human physiology and research fellow, Wroclaw Medical University, Poland
  • Former Director of Cardiac Rehabilitation, Saint John Paul II Specialist Hospital, Wroclaw, Poland
  • Former holder of EU scholarship in Department of Cardiology, Free University, Amsterdam, The Netherlands
  • Former lecturer in cardiology (EU scholarship) at Postgraduate School of Cardiology, University of Perugia, Italy
  • Former expert reviewer of research projects on cardiovascular medicine and physiology funded by European Commission and European Union countries
  • Chairperson of main session at EuroEcho-Imaging Congress 2018 (one of the most prestigious cardiology events worldwide), Milan, Italy

Directors

[Under NDA]

Founder - CEO

Lou Hawthorne

Laurence Marton, MD.

[Under NDA]

Founder - CEO

Lou Hawthorne

Lou Hawthorne is the founder and CEO of NaNotics, LLC, and is the inventor of the company’s core technology. Lou is an entrepreneur with 25 years’ experience in founding and leading companies developing new technologies in biotech/life science and information technology, including reproductive cloning, human IVF, oncology, and artificial intelligence.

In 2002, Lou co-founded the cloning companies Genetic Savings & Clone, and Viagen, Inc. acquired by Intrexon (XON) in 2014.

In 2014, Lou conceived and developed the concept of immune modulating nano-extractors (‘NaNots’), and founded NaNotics LLC., which is currently developing NaNots for treating cancer, sepsis, autoimmune disease and aging.

Lou is an experienced company leader with an extensive track record in funding, assembling and managing senior level multi-disciplinary teams for effective development of new technologies. He has collaborated closely with company co-founder, John Dodgson, PhD, a physical chemist and IP expert, for nearly two decades.

Lou is also an expert at brand development and strategic media, having designed global media campaigns that reached millions of people and generated profile valued at hundreds of millions of dollars. He has been interviewed by most major newspapers, magazines, and television programs, including appearances on The Oprah Winfrey Show and Good Morning America.

Lou holds a B.A. in English Literature from Princeton University, where he was a University Scholar and recipient of the Ward Mathis prize.

Laurence Marton, MD.

Dr. Marton joined our board in September. He brings a wealth of experience in science, medicine, management and corporate governance – ranging from startups to established corporations. Dr. Marton serves as Trustee of the American Association for Cancer Research Foundation (AACR) and as Director of Cancer Commons. In the for-profit sector, he serves on the Boards of Cellsonics, Dategra, Matternet, Microsonic Systems, Pathologica, RenovoRx, Trident Laboratories, and xCures; is Chair of the Scientific Advisory Board of PharmaJet; is an advisor to Ciitizen, Enable Medicine, Immunai, and the Precision Medicine World Conference; and is on the Editorial Board of the Journal of Precision Medicine. Previously, Dr. Marton was Dean of the University of Wisconsin Medical School and Chaired the Department of Laboratory Medicine at UCSF, where he was a Professor in the Departments of Laboratory Medicine and Neurological Surgery. Dr. Marton received his MD from the Albert Einstein College of Medicine and his BA from Yeshiva University. Dr. Marton is bullish on the potential of NaNots and is already tapping his network for potential partners, consultants and investors. 

Careers

Open Positions

None at this time.